
Pfizer COVID-19 Vaccine Vials May Contain More Doses than Previously Thought
Up to 40% more doses—or, enough to vaccinate another person with two doses—has been observed in the vials distributed at the beginning of this week.
The early distribution of the first
Pharmacists administering the first doses of two-dose mRNA vaccine BNT162b2, from Pfizer and BioNTech, have observed the advised five-dose vials distributed in lots to designated administration sites could actually hold a sixth or even seventh dose in each supply.
Now, the US Food and Drug Administration (FDA) has walked back its labeling information from the Emergency Use Authorization (EUA) granted to the vaccine last week, permitting pharmacists to use the additional doses.
Experts
A Pfizer spokesperson said the amount of vaccine available after 5 doses are used can vary based on needles and syringes used. They advised vaccinators consult their own institution’s policies on use.
Officials, however, did advise that excess vaccine should never be pooled with that left over from other vials.
At the time of the
Through the agreement, the federal government would receive 100 million BNT162b2 doses upon EUA approval, for a cost of $1.95 billion and an option to acquire another 500 million doses.
Very suddenly, Pfizer’s vaccine contribution in 2021 may vary anywhere from 1.3 billion to nearly 2 billion—which, as a two-dose vaccine, would provide protection to 1 billion people.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.